Loading…
Loading…
Toronto, Ontario--(Newsfile Corp. - Le 19 septembre/September 2025) - The common shares of Core One Labs Inc. will be delisted from the CSE at market close today, September 19, 2025. Core One Labs Inc. is currently suspended.
VANCOUVER, BC / ACCESSWIRE / July 8, 2024 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has entered into a loan agreement (the "Loan Agreement") with Right Season Investments Corp. ("Right Season") dated June 28, 2024. Under the terms of the Loan Agreement, Right Season has advanced a loan of CDN$300,000 (the "Loan") to the Company.
VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce the signing of an Initial Agreement (the "Agreement") with Cube Psytech Corp. ("Cube Psytech") marking a significant step towards exploring the potential sale of biosynthetically produced psilocybin, or the licensing of its proprietary method for biosynthetic psilocybin production technology. This Agreement with Cube Psytech could set the stage for Core One products to enter the international market.
VANCOUVER, BC / ACCESSWIRE / December 1, 2023 / Core One Labs Inc. ("Core One" or the "Company") (CNSX:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU), an emerging leader in the field of neuroscience and psychedelics, is delighted to share the exciting results of its first round of Stage 2 animal model studies, carried out in collaboration with the Universitat de Barcelona on behalf of the Company's wholly owned subsidiary, Akome Biotechnologies Inc. ("Akome"). The results of the studies so far demonstrate promising outcomes, showing potential to outperform current treatment methods for Alzheimer's and Parkinson's, and marking a significant step forward in the Company's pursuit of innovative treatment alternatives for common neurodegenerative diseases and mental health conditions.
VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU), (the "Company" or "Core One") is delighted to announce the receipt of additional positive results from its second round ("Round 2") of Stage 1 animal model studies. The groundbreaking studies were conducted in collaboration with esteemed research partners at the Universitat de Barcelona, Spain, and were carried out on behalf of Core One's wholly owned subsidiary, Akome Biotechnologies Inc. ("Akome").
Core One's Wholly-Owned Subsidiary has filed a patent application with the United States Patent and Trademark Office VANCOUVER, BC / ACCESSWIRE / August 1, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") proudly announces a significant milestone in its pursuit of cutting-edge psychedelic research and development. Awakened Biosciences Inc. ("Awakened"), Core One's wholly-owned subsidiary, has filed a patent application titled "Isolation and Purification of Psilocybin via Formation of Salts with Strong Organic Acids" with the United States Patent and Trademark Office (USPTO).
VANCOUVER, BC / ACCESSWIRE / July 28, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), is excited to share positive results from its first round of Stage 1 animal model studies ("Round 1"), conducted by its research partners at the Universitat de Barcelona ("University of Barcelona" or the "University" or the "Investigators"), Barcelona, Spain, on behalf of the Company's wholly owned subsidiary, Akome Biotechnologies Inc. ("Akome"). Akome's Stage 1 animal model studies ( in vivo , or within living organisms) use the nematode Caenorhabditis elegans ("C.
VANCOUVER, BC / ACCESSWIRE / July 21, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN: A3CSSU) (the "Company" or "Core One") is pleased to announce that its wholly-owned subsidiary, GMP Drug Inc. ("GMP Drug"), has entered into a non-binding letter of intent (the "LOI") with Zollaris Laboratories Corporation ("Zollaris"), an arms-length party, in pursuit of a potential transaction involving the sale by GMP Drug (the "Supply Arrangement") of psychedelic compounds including but not limited to biosynthetic psilocybin, psilocin, DMT formulated by Vocan Biotechnologies Inc. ("Vocan") and Awakened Biosciences Inc. ("Awakened"), each also wholly-owned subsidiaries of Core One. Zollaris is a licensed pharmaceutical company that currently holds a license to possess, and conduct laboratory analysis on, psilocybin.
No recent filings indexed.